The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Multi-omic single-cell sequencing for myeloma mutation analysis
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the results of a study investigating the downstream effects of clonal hematopoiesis (CH) mutations using multi-omic single-cell sequencing of stem cells from multiple myeloma patients in remission. The study found that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
